TRDA Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. (TRDA) is expected to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is a loss of $0.98 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.1% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Entrada Therapeutics, Inc.
Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON.
Sector
Healthcare
Industry
Biotechnology